hVIVO Holdings Ltd is a United Kingdom-based company. The Company is engaged in sciences business pioneering a technology platform of human disease models to accelerate drug discovery and in respiratory and infectious diseases, including flu, respiratory syncytial virus (RSV), asthma and common cold.

Employees

Sector

Healthcare Facilities & Services

More about the company

Delayed London S.E.			5-day change	1st Jan Change
- ^GBX	-.--%		+18.92%	+41.94%

09-15	HVIVO Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2026	CI
09-15	HVIVO CFO to Step Down; Interim CFO Named	MT

Market Cap	13.8M 18.23M 16.29M 15.2M 26M 1.76B 26.19M 183M 71.35M 897M 68.45M 66.96M 2.88B	P/E 2023	7.02x	P/E 2024	10.6x
Enterprise Value	-17.47M -23.08M -20.62M -19.24M -32.91M -2.23B -33.16M -231M -90.32M -1.14B -86.64M -84.77M -3.65B	EV / Sales 2023	-0.19x	EV / Sales 2024	-0.28x
Free-Float	91.04%	Yield 2023	1.21%	Yield 2024	1.21%

09-15	HVIVO Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2026	CI
09-15	HVIVO CFO to Step Down; Interim CFO Named	MT
09-15	Earnings Flash (HVO.L) hVIVO plc Reports H1 Revenue GBP16.3M	MT
09-15	Earnings Flash (HVO.L) hVIVO plc Posts H1 Loss GBX-0.94	MT
08-27	HVIVO Acquires German Research Institute CRS Clinical Research	MT
05-07	HVIVO Secures GBP6 Million Deal to Run Influenza Human Challenge Trial for Monoclonal Antibody	MT
04-22	HVIVO to Run Late-stage Human Challenge Trial for ILiAD's Whooping Cough Vaccine Candidate	MT
04-15	HVIVO Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-14	Hvivo plc Signs Clinical Trial Agreement with Traws Pharma	CI
04-14	HVIVO to Run Phase 2a Influenza Challenge Trial for Traws Pharma's Antiviral Candidate	MT
25-09-23	HVIVO Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-07-29	Hvivo Names New Nonexecutive Chairman	MT
25-04-10	HVIVO Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2024	CI

25-02-04	Inhalon Biopharma Announces First-of-its-Kind Inhaled Antibody Treatment for RSV to Enter Human Clinical Trials	AQ
24-04-09	HVIVO achieves record revenue and initiates dividend policy following successful year	AQ
24-02-20	HVIVO chairman Cathal Friel says he remains committed to hVIVO following share sale	AQ
24-01-02	HVIVO secures Ã‚£6.3 million challenge contract	AQ
23-12-13	HVIVO secures fresh contract to round out "wonderful" year	AQ

hVIVO plc Stock

Stocks

HVO

GB00B6ZM0X53

Healthcare Facilities & Services

Valuation: hVIVO plc

Latest news: hVIVO plc

Press Releases: hVIVO plc

News in other languages: hVIVO plc

Managers and Directors: hVIVO plc

Latest insider transactions

Other Healthcare Facilities & Services

Financials

Company Profile

21-02-17	WDH/Britische Wissenschaftler wollen Freiwillige mit Corona infizieren
20-09-25	Absichtliche Corona-Infektionen: Ein guter Weg zum Impfstoff?

Manager	Title	Age	Since
Mohammed Khan CEO	Chief Executive Officer	57	2022-01-31
Stephen Pinkerton DFI	Director of Finance/CFO	63	-
Thomas Andreas Forst CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Cathal Friel CHM	Chairman	62	2020-03-31
Brendan Buckley BRD	Director/Board Member	76	-
Mohammed Khan BRD	Director/Board Member	57	2022-01-31

Date	Insider	Type	Quantity	% Market Cap.
10/11/24	Yamin Khan	Free	4,606,794	5.5106%
6/14/23	Yamin Khan	Buy	13,526	0.0162%
2/6/23	Yamin Khan	Free	7,227,273	8.6452%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
HVIVO PLC	-.--%	+18.92%	-	-	18.04M
CVS HEALTH CORPORATION	+1.76%	+2.64%	+14.04%	+25.82%	111B
HCA HEALTHCARE, INC.	+1.61%	+2.91%	+0.37%	+78.98%	93.57B
NATERA, INC.	-1.27%	-4.29%	+134.71%	+808.29%	57.75B
FRESENIUS SE & CO. KGAA	-0.21%	-0.96%	-6.06%	+55.95%	27.77B
QUEST DIAGNOSTICS INCORPORATED	-0.58%	-2.58%	+24.83%	+82.72%	25.21B
LABCORP HOLDINGS INC.	+0.08%	+1.25%	+11.57%	+54.91%	25.28B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	-0.18%	+0.71%	-16.14%	-2.69%	21.31B
TENET HEALTHCARE CORPORATION	+0.53%	+1.67%	+26.85%	+321.39%	20.81B
REDE D'OR SÃO LUIZ S.A.	-0.60%	+15.93%	+8.61%	+81.18%	19.55B
Average	+0.11%	+3.57%	+22.09%	+167.39%	40.18B
Weighted average by Cap.	+0.62%	+0.32%	+26.13%	+174.64%

	2023	2024
Net sales	56.04M 74.02M 66.13M 61.7M 106M 7.16B 106M 741M 290M 3.64B 278M 272M 11.71B	62.72M 82.84M 74.02M 69.06M 118M 8.01B 119M 830M 324M 4.08B 311M 304M 13.1B
Net income	16.11M 21.28M 19.02M 17.74M 30.35M 2.06B 30.58M 213M 83.29M 1.05B 79.9M 78.17M 3.37B	10.65M 14.07M 12.57M 11.73M 20.06M 1.36B 20.21M 141M 55.06M 692M 52.81M 51.67M 2.22B
Net Debt	-24.44M -32.28M -28.84M -26.91M -46.04M -3.12B -46.38M -323M -126M -1.59B -121M -119M -5.11B	-31.28M -41.31M -36.91M -34.44M -58.91M -4B -59.35M -414M -162M -2.03B -155M -152M -6.53B